EGFR and non-small cell lung carcinoma: The significance of KRAS mutations as a biomarker for NSCLC, remains elusive and although it has been linked with resistance to anti-EGFR therapy, recent bibliography suggests a possible clinical significance amongst the various KRAS mutations [50, 52].